Drugs / BIA 5-1058
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04069130 | Jan → May 2019 | cardiovascular disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT07173738 | Jun → Sep 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03708146 | May 2018 → Mar 2019 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03489005 | Apr → Oct 2018 | heart failure, pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04994860 | Mar → Jun 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04675944 | Feb → May 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04994119 | Feb → May 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04991207 | Feb → May 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04991181 | Mar → May 2017 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04991194 | Oct 2015 → Dec 2016 | pulmonary arterial hypertension | Bial - Portela C S.A. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04991155 | Jul → Sep 2015 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02151994 | Mar 2011 → Jan 2012 | hypertensive heart disease | Bial - Portela C S.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIA 5 1058 | “Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows: * 400 mg BIA 5 1058, as 4 × 100 mg...” NCT03489005 ↗ |
| Action | Inhibit | “To investigate CYP2C9 inhibition by BIA 5-1058” NCT04994119 ↗ |
| Route | Oral | “oral administration” NCT02151994 ↗ |
| Target | CYP2C9 | “To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.” NCT04994119 ↗ |